Kolon Life Science Q1 Operating Profit Turns Black, Equity Surges
- Consolidated revenue KRW 49.6bn (+10.8% YoY), operating profit KRW 2.9bn (turnaround from KRW 0.07bn in prior year Q1)
- Net income for the quarter KRW 20.8bn (down from KRW 25.0bn in prior year Q1), total equity KRW 784.1bn (+34% from year-end 2025) – reflects fair value gains on FVOCI financial assets (Kolon TissueGene shares)
- TG-C (Invossa) technology export contract: total up to KRW 723.4bn with Pine Pharmaceuticals, upfront KRW 15bn received
- Bio business continues operating loss of KRW 6.4bn; KLS-2031 phase 1/2a paper published, diabetic neuropathic pain preclinical paper submitted
- Invossa product license revocation lawsuit ongoing; 32 damage claim lawsuits pending (provision recognized)
- All series 6 convertible bonds (KRW 12bn) converted; issuance of series 3 and 9 hybrid bonds (total KRW 55bn) bolstered capital
- No dividends or share buyback/cancellation
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Quarterly Report (2026.03)
- Company: KOLON LIFE SCIENCE (102940)
- Submission: KOLON LIFE SCIENCE Inc.
- Receipt: 05-15-2026